Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

If you feel your psoriasis treatment is not producing what you seek here are 10 key factors that might be hindering your ...

Arcutis Biotherapeutics is a standout in biotech with FDA-approved ZORYVE and strong potential. See why we recommend a buy on ...

US-based biotechnology company Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15%, is indicated ...

A new study links abdominal fat, especially in women, to increased risk of psoriasis, regardless of genetic predisposition, ...

New research led by scientists at the University of Birmingham suggests that treating psoriasis with a tripeptide-composed of ...

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

VedicDerm launches a steroid-free Ayurvedic psoriasis cream, scientifically proven to reduce inflammatory markers by up to 99%. Offers new hope for millions.